Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$111.40M+1296.05%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa Graver
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,279
- Beta
- 0.18
- Country
- LU
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.37
Financials
Revenue
$111.40M+1296.1%Net Income
$-74.87MEBITDA
$24.01MFree Cash Flow
$-130.75MEPS (diluted)
$-0.23Shares Outstanding (diluted)
327.94M+34.6%Operating Expenses
$46.93MCash & Debt
$61.47MReturn of Capital
$0.00Revenue by Segment (annual)
$12.20BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $586.32M | $27.92M | $0.10 |
| 2024 | $489.68M | $-231.86M | $-0.87 |
| 2023 | $91.43M | $-551.73M | $-2.43 |
| 2022 | $83.03M | $-513.58M | $-2.60 |
| 2021 | $36.77M | $-101.50M | $-3.25 |
| 2020 | $66.62M | $-170.04M | $-5.44 |
| 2019 | $31.92M | $-209.88M | $-0.86 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.15
- Implied price
- $7.49
- Return from $4.19
- 12.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.73 — -11.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| -2.0% | -5.5% | -1.5% | 1.9% | 4.9% | 7.6% |
| 3.0% | -0.6% | 3.5% | 7.1% | 10.3% | 13.1% |
| 8.0% | 4.2% | 8.6% | 12.3% | 15.7% | 18.6% |
| 13.0% | 9.0% | 13.6% | 17.5% | 21.0% | 24.1% |
| 18.0% | 13.8% | 18.6% | 22.7% | 26.4% | 29.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (16)
- Newsmarketbeat.com·10d ago·Neutral
What Alvotech (ALVO) Said on Its Q3 Earnings Call Alvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.
View source ↗ - Newsseekingalpha.com·19d ago·Neutral
…tech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half revenue and EBITDA ramp, hinging on restored manufacturing capacity and upcoming product launches. Recent manufacturing upgrades and expanded partnerships position ALVO to compete on supply reliability and cost, crucial in crowded biosimilar markets.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Alvotech to Present at Upcoming Investor Conferences in November REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
View source ↗ - Newsglobenewswire.com·47d ago·Negative
…ip to increase Alvotech's global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will …
View source ↗ - Newsglobenewswire.com·48d ago·Negative
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira® Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·83d ago·Negative
…cense Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (v…
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Alvotech to present at upcoming investor conferences in September REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
View source ↗ - Newsglobenewswire.com·93d ago·Neutral
… for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selecte…
View source ↗ - Newsseekingalpha.com·94d ago·Negative
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large ma
View source ↗ - Newsmarketbeat.com·94d ago·Neutral
Alvotech Q2 Earnings Call Highlights Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.
View source ↗ - Newszacks.com·95d ago·Neutral
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗
Earnings
Wed, Mar 17(in 4 months)
Consensus estimate $0.21 per share
Typical surprise +12.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 11$-0.03 vs $-0.03miss
- Wed, Aug 19$-0.11 vs $-0.05miss
- Wed, May 6$-0.09 vs $-0.07miss
- Wed, Mar 18$-0.37 vs $-0.01miss
- Wed, Nov 12$-0.02 vs $-0.03beat
- Wed, Aug 13$0.14 vs $-0.05beat
Estimates and results for ALVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ALVO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
